Hantz Financial Services Inc. Has $3.63 Million Stake in CVS Health Corporation $CVS

Hantz Financial Services Inc. boosted its position in CVS Health Corporation (NYSE:CVS) by 1.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 52,553 shares of the pharmacy operator’s stock after buying an additional 501 shares during the period. Hantz Financial Services Inc.’s holdings in CVS Health were worth $3,625,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Goldman Sachs Group Inc. grew its stake in CVS Health by 87.5% during the first quarter. Goldman Sachs Group Inc. now owns 9,927,650 shares of the pharmacy operator’s stock worth $672,598,000 after purchasing an additional 4,632,530 shares during the period. Dodge & Cox boosted its holdings in shares of CVS Health by 4.8% during the 1st quarter. Dodge & Cox now owns 73,459,122 shares of the pharmacy operator’s stock worth $4,976,856,000 after buying an additional 3,353,223 shares in the last quarter. Nuveen LLC bought a new position in shares of CVS Health during the 1st quarter worth approximately $204,421,000. Invesco Ltd. lifted its position in shares of CVS Health by 13.2% during the 1st quarter. Invesco Ltd. now owns 20,413,853 shares of the pharmacy operator’s stock valued at $1,383,039,000 after acquiring an additional 2,375,764 shares during the period. Finally, Robeco Institutional Asset Management B.V. lifted its position in shares of CVS Health by 815.2% during the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 2,663,111 shares of the pharmacy operator’s stock valued at $183,701,000 after acquiring an additional 2,372,121 shares during the period. 80.66% of the stock is owned by institutional investors.

CVS Health Trading Up 1.9%

Shares of CVS Health stock opened at $78.13 on Friday. The company has a current ratio of 0.83, a quick ratio of 0.62 and a debt-to-equity ratio of 0.83. The company has a market capitalization of $99.09 billion, a P/E ratio of 205.61, a price-to-earnings-growth ratio of 0.87 and a beta of 0.60. The stock has a fifty day simple moving average of $76.49 and a 200 day simple moving average of $69.04. CVS Health Corporation has a 12-month low of $43.56 and a 12-month high of $85.15.

CVS Health (NYSE:CVS) last posted its quarterly earnings data on Wednesday, October 29th. The pharmacy operator reported $1.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.36 by $0.24. CVS Health had a net margin of 0.12% and a return on equity of 11.45%. The firm had revenue of $102.87 billion for the quarter, compared to the consensus estimate of $98.85 billion. During the same period in the previous year, the firm earned $1.09 EPS. The business’s revenue for the quarter was up 7.8% compared to the same quarter last year. CVS Health has set its FY 2025 guidance at 6.550-6.650 EPS. On average, sell-side analysts anticipate that CVS Health Corporation will post 5.89 earnings per share for the current fiscal year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Thursday, October 23rd will be paid a $0.665 dividend. The ex-dividend date is Thursday, October 23rd. This represents a $2.66 annualized dividend and a yield of 3.4%. CVS Health’s dividend payout ratio (DPR) is 74.30%.

Insider Activity

In other news, Director Anne A. Finucane sold 7,500 shares of the company’s stock in a transaction that occurred on Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total value of $532,650.00. Following the completion of the transaction, the director directly owned 22,156 shares of the company’s stock, valued at $1,573,519.12. This represents a 25.29% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 1.22% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have recently commented on the company. Sanford C. Bernstein raised their target price on CVS Health from $72.00 to $77.00 and gave the company a “market perform” rating in a research note on Friday, September 5th. Cantor Fitzgerald increased their price target on CVS Health from $78.00 to $95.00 and gave the stock an “overweight” rating in a report on Thursday. Jefferies Financial Group upped their target price on CVS Health from $80.00 to $92.00 in a research report on Wednesday, October 15th. Wolfe Research upped their target price on CVS Health from $80.00 to $85.00 and gave the stock an “outperform” rating in a research report on Monday, September 22nd. Finally, Royal Bank Of Canada boosted their price target on shares of CVS Health from $81.00 to $93.00 and gave the company an “outperform” rating in a research note on Thursday. Two analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating and four have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $86.33.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.